Recommendations for the surgical management of gynecological cancers during the COVID-19 pandemic - FRANCOGYN group for the CNGOF

Akladios, Chérif; Azaïs, Henri; Ballester, Marcos; Bendifallah, Sofiane; Bolze, Pierre‐Adrien; Bourdel, Nicolas; Bricou, Alexandre; Canlorbe, Geoffroy; Carcopino, Xavier; Chauvet, Pauline; Collinet, Pierre; Coutant, Charles; Dabi, Yohann; Dion, Ludivine; Gauthier, Tristan; Graesslin, Olivier; Huchon, Cyrille; Koskas, Martin; Kridelka, Frédéric; Lavoué, Vincent; Lecointre, Lise; Mezzadri, M.; Mimoun, Camille; Ouldamer, Lobna; Raimond, Émilie; Touboul, Cyril

doi:10.1016/j.jogoh.2020.101729

Cited by 102 publications

(134 citation statements)

References 0 publications

Supporting

Mentioning

122

Contrasting

Unclassified

Order By: Relevance

“…33,34 In addition, an American multiorganizational panel has published recommendations on the triage, prioritization, and treatment of breast cancer 53 and an international group has also published recommendations on the same topic. 54 Currently, cancer type specific guidance has been developed for a number of cancers including gastrointestinal cancer, 55,56 genitourinary cancers, 57,58,60 gynecological cancers, 59,60 head and neck cancer, 61,62 hematological malignancy, 63,64 hepatocellular carcinoma, 65 lung cancer, 66 neuroncology, 67 and skin cancer. 68 The Society of Surgical Oncology has published a brief guidance on surgery which is specific for each type of cancer.…”

mentioning

confidence: 99%

Developing a holistic contingency plan: Challenges and dilemmas for cancer patients during the COVID‐19

et al. 2020

View full text Add to dashboard Cite

During the first quarter of 2020 the world is experiencing a pandemic of Severe Acute Respiratory Syndrome‑Coronavirus‑2 (SARS‑CoV‑2), a novel beta coronavirus that is responsible for the 2019 novel coronavirus disease (COVID‐19). The COVID‐19 pandemic revealed that healthcare systems around the world were not prepared to deal with either the direct effects of the pandemic or with the indirect effects that are imposed on the health of patients with chronic disorders such as cancer patients. Some challenges and dilemmas currently faced during the pandemic include the management of cancer patients during the treatment and follow‐up phases, the assessment of the safety of treatments currently used for the management of SARS‑CoV‑2 for use in cancer patients, the development of psychoeducation and emotional support for cancer patients and the safe conduct of clinical trials involving participation of cancer patients. Evidence from the literature supports the need for the urgent development of a holistic contingency plan which will include clear guidelines for the protection and comprehensive care of cancer patients. The implementation of such a plan is expected to have many beneficial effects by mainly minimizing the increased morbidity and mortality of cancer patients that could result as an adverse consequence of the COVID‐19 or future pandemics.

show abstract

mentioning

confidence: 99%

Developing a holistic contingency plan: Challenges and dilemmas for cancer patients during the COVID‐19

et al. 2020

View full text Add to dashboard Cite

show abstract

“…We here summarize some of these guidelines:  In gynecological cancer, the FRANCOGYN group for the CNGOF propose recommendations that do not differ much from the standard of care, except that they emphasize on radio-chemotherapy in the first line setting for cervical cancer instead of surgical treatment, and on the neoadjuvant chemotherapy for advanced ovarian cancer even for tumors that are judged to be resectable in order to reduce high risk surgeries and long ICU stays (80). Note that similar suggestions were proposed by a multinational group of practitioners (81).…”

Section: The French Experiencementioning

confidence: 99%

Cancer patients and research during COVID-19 pandemic: A systematic review of current evidence

Moujaess

Kourié

Ghosn

2020

Critical Reviews in Oncology/Hematology

189

200

View full text Add to dashboard Cite

The novel coronavirus, also known as SARS-Cov-2 or COVID-19 has become a worldwide threat and the major healthcare concern of the year 2020. Cancer research was directly affected by the emerging of this disease. According to some Chinese studies, cancer patients are more vulnerable to COVID-19 complications. This observation led many oncologists to change their daily practice in cancer care, without solid evidence and recommendations. Moreover, the COVID-19 manifestations as well as its diagnosis are particular in this special population. In this review paper we expose the challenges of cancer management in the era of SARS-CoV-2, the epidemiological, clinical, pathological and radiological characteristics of the disease in cancer patients and its outcomes on this population. Finally, we focus on strategies that are followed in cancer management with review of national and international guidelines. J o u r n a l P r e -p r o o f electronic search of the literature was conducted in the PubMed database until the 5th of April 2020. The following keywords with Boolean operators were used 'covid-19', 'novel coronavirus'and 'SARS-CoV-2' in combination with 'cancer', 'neoplasm', 'oncology' and 'malignancy'. A total of 223 articles were extracted. We included articles in English as well as articles in French because we are familiar with this language. Abstracts in English of articles in Chinese language were also J o u r n a l P r e -p r o o f 3 included. Duplicated articles and articles that were published before the era of SARS-Cov-2 (i.e., before December 2019) were excluded. Titles and abstracts of retrieved articles were screened for eligibility, and then entire texts were analyzed and 88 papers that respond to our objectives were included in this review. Our work is summarized in the PRISMA diagram below. ResultsOut of 88 articles, six were in French language and 19 were in Chinese language with English abstracts. Most of the papers consisted of short editorials, letters, correspondence or comments.Ten Cohort studies were identified (retrospective, prospective or cross-sectional analysis) as well as 9 case reports and one case series. Only four of the cohort studies exclusively included cancer patients. Of note, all cohort studies were conducted in China. Most of the reported cases originated from China and Italy.59% of the published papers originated from China and Italy (52 of 88). Seven works were multinational and the majority of them were multicontinental, issued in collaboration between researchers from Asia, Europe and the Americas. We identified one article originating from each of the following countries: Canada, India, Singapore, Spain and Saudi Arabia. The pie chart below

show abstract

“…There are several guidelines published to give recommendations on the safe gynecologic practice and the treatment of gynecologic patients during the ongoing pandemic, focusing onthe management of cancer patients [7][8][9][10][11][12]. Whenthe outbreak peak is gone and the lockdown is lifted, the medical resources should be redirected to none-COVID-19 patients, while the threats of COVID-19 transmission still exist.…”

Section: Introductionmentioning

confidence: 99%

Resumption of the Treatment for Non-COVID-19 Gynecologic Patients after Lifting Lock down: Experiences from Wuhan

Dong

Gao

Cai

et al. 2020

Preprint

View full text Add to dashboard Cite

Background: To share our experiences of resumption of the treatment for gynecologic patients after lifting lockdown in a hotspot area of the Corona Virus Disease 2019 (COVID-19)pandemic.Methods: The triage process used to resume the medical activities for gynecologic patients at the Wuhan Union Hospital after a 76-day lockdown of the city is described and its effectiveness to avoid COVID-19 nosocomial transmission is shown.Results:The non-emergency patients are pre-triaged by contact history and body temperature at outpatient clinic and negative COVID-19 screening tests are required for an admissionin the buffering rooms at the gynecologic department. The buffering lastsfor at least three days for symptom monitoring and a second round of COVID-19 tests before they can be transferred to the regular gynecologic wards. For patients who need emergency surgery, the first screening should be completed at the quarantine wards after the surgery, followed by buffering at the gynecologic department. We received 19298 outpatient visits, admitted 326 patients, and performed 223 operations in the first two months after the lockdown was lifted, andno single COVID-19 case occurredin the hospitalized patients while the proportion of potentially high-risk patients with cancer and severe anemia were increased in comparison with the same period in 2019 and the latest two months before the lockdown.Conclusions:We provide an effective triage system with buffering at two levels to guarantee safe and timely treatment for non-COVID-19 gynecologic patients in a post-lockdown phase.

show abstract

Recommendations for the surgical management of gynecological cancers during the COVID-19 pandemic - FRANCOGYN group for the CNGOF

Cited by 102 publications

References 0 publications

Developing a holistic contingency plan: Challenges and dilemmas for cancer patients during the COVID‐19

Developing a holistic contingency plan: Challenges and dilemmas for cancer patients during the COVID‐19

Cancer patients and research during COVID-19 pandemic: A systematic review of current evidence

Resumption of the Treatment for Non-COVID-19 Gynecologic Patients after Lifting Lock down: Experiences from Wuhan

Contact Info

Product

Resources

About